Follicular lymphoma is a slow-growing blood cancer that requires a thoughtful approach to treatment, balancing the goal of controlling the disease with maintaining quality of life. While the condition is not currently curable, advances in therapy have significantly extended survival times, and many people live for years managing this chronic illness. Treatment decisions depend on the stage of disease, the presence or absence of symptoms, and individual patient factors, making personalized care essential.

How Follicular Lymphoma Treatment Works

The primary goal when treating follicular lymphoma is to reduce the number of cancer cells in the body, ease symptoms when they occur, and help people maintain the best possible quality of life. Unlike some cancers where immediate treatment is standard, follicular lymphoma often grows so slowly that treatment may not be needed right away. This approach reflects the unique nature of the disease: it tends to behave as a chronic condition rather than an aggressive emergency.^[1][2]

Treatment planning takes into account several important factors. The stage of the disease matters greatly—whether the lymphoma is confined to one area or has spread throughout the body influences which therapies doctors recommend. The grade of the lymphoma, which describes how the cancer cells look under a microscope and how quickly they are likely to grow, also plays a role. Grade 1, 2, and 3A follicular lymphomas are considered slow-growing, while grade 3B grows faster and may require treatment similar to more aggressive lymphomas.^[8]

Individual patient characteristics are equally important. Age, overall health, the presence of other medical conditions, and personal preferences all shape treatment decisions. Some people may prefer to delay treatment and avoid side effects for as long as possible, while others may feel more comfortable beginning therapy even if symptoms are mild. There is no single “right” answer—what matters is finding an approach that aligns with each person’s medical needs and life circumstances.^[10]

Medical societies and expert groups have developed clinical guidelines to help doctors make treatment recommendations. These guidelines are based on research studies involving thousands of patients and provide a framework for care. However, guidelines are not rigid rules; they serve as starting points that doctors adapt to fit individual situations. The best outcomes happen when patients and their healthcare teams work together to make informed decisions.^[11]

Standard Treatment Options

When follicular lymphoma does not cause symptoms, doctors often recommend active surveillance, sometimes called “watch and wait.” This strategy might sound unusual—choosing not to treat a cancer—but research has shown that people who delay treatment until symptoms develop live just as long as those who begin therapy right away. Active surveillance involves regular checkups, blood tests, and imaging scans to monitor the disease. Treatment begins only if the lymphoma starts to grow, causes symptoms, or threatens to affect important organs.^[2][10]

The benefit of active surveillance is that it allows people to avoid the side effects of treatment for as long as possible. Chemotherapy, radiation, and other therapies can cause fatigue, nausea, hair loss, and increase the risk of infections. By waiting, patients preserve their quality of life and save more aggressive treatments for when they are truly needed. However, living with untreated cancer can be emotionally challenging for some people, and the decision to watch and wait should be made carefully with input from healthcare providers.^[13]

Radiation therapy is often used when follicular lymphoma is localized, meaning it affects only one or two areas of the body (stage I or early stage II). Radiation uses high-energy beams to destroy cancer cells in a specific location. For some patients with early-stage disease, radiation alone can lead to long-lasting remission—periods where the cancer is not detectable and causes no symptoms. Approximately half of people treated with radiation for localized follicular lymphoma remain in remission for many years.^[2][9]

Radiation is typically given over several weeks, with treatments administered a few times per week. Each session lasts only a few minutes, and the process is painless, though some people experience fatigue or skin irritation in the treated area. Radiation therapy is highly targeted, meaning it focuses on killing cancer cells while minimizing damage to surrounding healthy tissue. The specific schedule and dose depend on the size and location of the lymphoma.^[10]

For more advanced disease, or when the lymphoma returns after radiation, doctors turn to systemic therapies—treatments that travel throughout the body to reach cancer cells wherever they are. One of the most important medications in the treatment of follicular lymphoma is rituximab, a type of monoclonal antibody. Monoclonal antibodies are laboratory-made proteins that target specific markers on cancer cells. Rituximab binds to a protein called CD20, which is found on the surface of the abnormal B lymphocytes (a type of white blood cell) that make up follicular lymphoma. Once rituximab attaches to these cells, it signals the immune system to destroy them.^[10][11]

Rituximab is often given alone or combined with chemotherapy. Chemotherapy uses drugs to kill rapidly dividing cells, including cancer cells. Common chemotherapy regimens for follicular lymphoma include R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone), and R-bendamustine (rituximab and bendamustine). Each of these combinations has a slightly different balance of effectiveness and side effects, and doctors choose based on the patient’s overall health, age, and how well they are likely to tolerate treatment.^[10][11]

Chemotherapy for follicular lymphoma is usually given in cycles—periods of treatment followed by rest periods to allow the body to recover. A typical cycle might last three weeks, and treatment may continue for several months. Side effects vary depending on the specific drugs used but can include nausea, fatigue, hair loss, increased risk of infection due to lower white blood cell counts, and damage to healthy cells in the bone marrow, digestive system, or other organs. Many of these side effects improve once treatment is finished, though some people experience long-lasting fatigue or other changes.^[13]

After completing initial chemotherapy and rituximab, some patients receive maintenance therapy with rituximab. This means continuing to receive rituximab infusions every two or three months for up to two years. The goal of maintenance therapy is to prolong the time before the lymphoma returns. Studies have shown that maintenance rituximab can extend remission, though not all doctors agree on whether every patient should receive it. Some research suggests the benefit is most pronounced in certain groups of patients, and the decision to use maintenance therapy should be individualized.^[10][11]

Another treatment option is radioimmunotherapy, which combines the targeting ability of a monoclonal antibody with the cancer-killing power of radiation. Yttrium-90 ibritumomab tiuxetan (Zevalin) is one such agent. It delivers radiation directly to cancer cells throughout the body by attaching a radioactive particle to an antibody that seeks out lymphoma cells. This approach can be effective but is less commonly used than other treatments and requires special handling and facilities.^[10]

CAR T-cell therapy is a newer treatment that has shown promise for people with follicular lymphoma that has returned after other treatments. CAR T-cell therapy involves collecting a patient’s own immune cells, genetically modifying them in a laboratory to recognize and attack lymphoma cells, and then infusing them back into the patient. This therapy can be highly effective but also carries significant risks, including severe immune reactions and neurological side effects. It is typically reserved for people who have already tried multiple other treatments.^[1][12]

Experimental Treatments in Clinical Trials

Clinical trials are research studies that test new treatments or new combinations of existing treatments. For follicular lymphoma, clinical trials are exploring innovative therapies that target the disease in different ways than standard treatments. Participating in a clinical trial can give patients access to cutting-edge therapies that are not yet widely available, though it is important to understand that experimental treatments may not work better than existing options and may have unknown risks.^[11][12]

One area of active research involves drugs that block specific molecular pathways inside cells. Follicular lymphoma cells rely on certain signals to survive and grow, and blocking these signals can kill the cancer. PI3K inhibitors are one example. The PI3K pathway is a chain of chemical reactions inside cells that helps them survive, grow, and divide. In follicular lymphoma, this pathway is often overactive. Drugs such as idelalisib, copanlisib, and duvelisib block this pathway, causing the cancer cells to die. These medications have been tested in clinical trials and are now approved for use in people whose lymphoma has returned after other treatments.^[12]

PI3K inhibitors are taken as pills or given by infusion. Early clinical trial results showed that these drugs can shrink lymphomas and improve symptoms in patients whose disease had not responded to other therapies. However, side effects can be significant and include diarrhea, rash, infections, liver inflammation, and lung problems. Because of these risks, PI3K inhibitors are typically used in people who have already tried multiple other treatments and whose disease cannot be controlled with standard therapies.^[12]

Another promising class of drugs being studied in clinical trials is EZH2 inhibitors. EZH2 is an enzyme involved in controlling which genes are turned on or off inside cells. In some cases of follicular lymphoma, the EZH2 gene is mutated, causing the enzyme to work abnormally and contributing to cancer growth. Drugs like tazemetostat block the activity of mutated EZH2, which can slow or stop the growth of lymphoma cells. Clinical trials have shown that tazemetostat can be effective in people whose lymphomas have the EZH2 mutation, with a reasonable safety profile. Common side effects include fatigue, nausea, and low blood cell counts.^[12]

EZH2 inhibitors represent a form of targeted therapy, meaning they are designed to attack cancer cells based on specific genetic characteristics. Not all follicular lymphomas have EZH2 mutations, so this treatment is only appropriate for a subset of patients. Genetic testing of the lymphoma cells can determine whether a person is likely to benefit from this type of therapy.^[12]

BTK inhibitors are another group of drugs being tested in clinical trials for follicular lymphoma. BTK, or Bruton tyrosine kinase, is a protein that helps B lymphocytes receive signals to grow and survive. Blocking BTK can disrupt these signals and kill lymphoma cells. Drugs like ibrutinib and zanubrutinib are BTK inhibitors that have been studied in patients with relapsed follicular lymphoma. Clinical trial results have shown modest activity, and research is ongoing to determine the best ways to use these drugs, either alone or in combination with other treatments.^[12]

Clinical trials for follicular lymphoma are conducted in phases, each with a different purpose. Phase I trials test the safety of a new drug, determine the correct dose, and identify side effects. These trials enroll a small number of patients and are the first step in evaluating whether a treatment is safe for humans. Phase II trials assess whether the treatment works—whether it can shrink tumors, improve symptoms, or delay disease progression. Phase II trials involve more patients and provide preliminary evidence of effectiveness. Phase III trials compare the new treatment to the current standard of care, often using a randomized design where some patients receive the experimental therapy and others receive the standard treatment. Phase III trials are large and provide the strongest evidence about whether a new treatment should be widely adopted.^[11]

Some clinical trials are testing combinations of new drugs with existing therapies. For example, researchers are studying whether adding PI3K inhibitors or EZH2 inhibitors to rituximab-based chemotherapy can improve outcomes. Other trials are exploring whether using newer monoclonal antibodies, such as obinutuzumab, which targets the same CD20 protein as rituximab but works slightly differently, can enhance the effectiveness of treatment.^[12]

Clinical trials for follicular lymphoma are being conducted around the world, including in the United States, Europe, and other regions. Eligibility to participate depends on many factors, including the stage and grade of the lymphoma, previous treatments, overall health, and the specific goals of the trial. Patients interested in clinical trials should discuss the option with their doctors, who can help determine whether a trial might be appropriate and how to find one. Online databases and resources provided by cancer organizations can also help people locate trials that are currently enrolling patients.^[11]

Most common treatment methods

• Active surveillance (watch and wait)
  • Regular monitoring with checkups, blood tests, and imaging scans without immediate treatment
  • Used when follicular lymphoma is not causing symptoms and is growing slowly
  • Allows patients to avoid treatment side effects until therapy is truly needed
• Radiation therapy
  • High-energy beams directed at localized areas of lymphoma
  • Most effective for stage I or early stage II disease
  • Can lead to long-lasting remission in about half of patients with limited disease
• Immunotherapy with monoclonal antibodies
  • Rituximab targets the CD20 protein on lymphoma cells and recruits the immune system to destroy them
  • Often used alone or combined with chemotherapy
  • Maintenance rituximab may be given for up to two years to prolong remission
  • Obinutuzumab is another CD20-targeting antibody being studied in clinical trials
• Chemotherapy
  • Common regimens include R-CHOP, R-CVP, and R-bendamustine
  • Given in cycles over several months
  • Side effects include nausea, fatigue, hair loss, and increased infection risk
• CAR T-cell therapy
  • Involves genetically modifying a patient’s immune cells to attack lymphoma
  • Used for relapsed or refractory follicular lymphoma after multiple prior treatments
  • Can be highly effective but carries risks of severe immune reactions and neurological side effects
• Targeted therapy
  • PI3K inhibitors (idelalisib, copanlisib, duvelisib) block a survival pathway in lymphoma cells
  • EZH2 inhibitors (tazemetostat) target tumors with specific genetic mutations
  • BTK inhibitors (ibrutinib, zanubrutinib) disrupt B-cell signaling
  • Used primarily in relapsed or refractory disease and being studied in clinical trials
• Radioimmunotherapy
  • Yttrium-90 ibritumomab tiuxetan (Zevalin) delivers radiation directly to lymphoma cells via an antibody
  • Combines the targeting of immunotherapy with the cancer-killing power of radiation
  • Less commonly used but can be effective in selected patients